Europe Biguanides Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The market is segmented by drug (metformin) and by geography.

Market Snapshot

europe biguanide market Overview
Study Period: 2018 - 2026
Base Year: 2020
europe biguanide market Key Players

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

  • The countries in the European region have a high prevalence of diabetes. The number of diabetic patients in Europe increased immensely in the past few years, due to factors, such as the increasing geriatric population in Europe and the increase in overweight and obese population, owing to unhealthy diets and physical inactivity.
  • As diabetes can potentially increase the risk of cardiovascular disease, it has to well manage by seeking suitable treatments at regular intervals of time.
  • The type 2 population in most countries in Europe accounts for about 90% of the diabetic population.
  • According to the WHO, in 2018, about 27 million people had diabetes in the European region.
  • Biguanides have become a mainstay of type 2 diabetes management and are the recommended first-line drug for treating the disease

Scope of the Report

The market is segmented by drug (metformin) and by geography.

By Drug Biguanides Metformin
By Region Europe United Kingdom
Germany
Spain
Italy
France
Russia
Rest of Europe

Report scope can be customized per your requirements. Click here.

Key Market Trends

Prevalence of diabetes is increasing among all ages in the European Region

  • The prevalence of diabetes is increasing among all ages in the European Region, mostly due to physical inactivity and obesity.
  • Obesity accounts for about 65% to 80% of new cases of type 2 diabetes in the region. In most of the European countries, more than one in five adults are obese.
  • This is mainly due to the unhealthy diet they follow. In the European countries, nearly 25% of their total daily energy intake comes directly from sugar, which is the primary cause of obesity, and in the future type 2 diabetes.
  • As most of the diabetic populations in this region are type 2 and as Biguanides considered as the first line drugs for type 2 patients, the market for these drugs is enormous in the region.
europe biguanide market Key Trends

Germany to dominate the Europe Biguanides Market.

  • In Europe Biguanide market, Germany accounts for the close to 46% of the total market value in 2018.
  • By 2024, the biguanide market in Germany is expected to grow marginally. Thus there is a moderate CAGR of 0.3% during the forecast period.
  • Russia accounts for the highest CAGR of 14.99% during the forecast period. This is mainly due to the increasing number of type two patients.
  • The Europe biguanide market is USD 1161.3 million in 2018 and expected to witness a CAGR of 2.35% during the forecast period.
europe biguanide market Growth by Region

Competitive Landscape

  • Biguanides are considered to be the first line treatment of drugs for type 2 diabetes patients. There are many companies which have a global presence manufacture Metformin drug. 
  • Thus, there is no particular company for which the metformin market share is segmented.  

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Drivers

    3. 4.3 Restraints

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Bargaining Power of Suppliers

      2. 4.4.2 Bargaining Power of Consumers

      3. 4.4.3 Threat of New Entrants

      4. 4.4.4 Threat of Substitute Products and Services

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Drug

      1. 5.1.1 Metformin (Value and Volume, 2012-2024)

    2. 5.2 Geography

      1. 5.2.1 Europe

        1. 5.2.1.1 Germany (Value and Volume, 2012-2024)

          1. 5.2.1.1.1 By Drug (Metformin)

        2. 5.2.1.2 Spain(Value and Volume, 2012-2024)

          1. 5.2.1.2.1 By Drug (Metformin)

        3. 5.2.1.3 Italy (Value and Volume, 2012-2024)

          1. 5.2.1.3.1 By Drug (Metformin)

        4. 5.2.1.4 France (Value and Volume, 2012-2024)

          1. 5.2.1.4.1 By Drug (Metformin)

        5. 5.2.1.5 United Kingdom (Value and Volume, 2012-2024)

          1. 5.2.1.5.1 By Drug (Metformin)

        6. 5.2.1.6 Russia (Value and Volume, 2012-2024)

          1. 5.2.1.6.1 By Drug (Metformin)

        7. 5.2.1.7 Rest of Europe (Value and Volume, 2012-2024)

          1. 5.2.1.7.1 By Drug (Metformin)

  6. 6. Competitive Landscape

    1. 6.1 Company Profiles

      1. 6.1.1 Mylan

      2. 6.1.2 Teva

      3. 6.1.3 Takeda

      4. 6.1.4 GlaxoSmithKline

      5. 6.1.5 Merck

      6. 6.1.6 Bristol-Myers Squibb

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITES AND FUTURE TRENDS

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Europe Biguanides Market market is studied from 2018 - 2026.

Mylan, Teva, Takeda, Ranbaxy/Sun Pharma, GlaxoSmithKline, Merck, Bristol-Myers Squibb are the major companies operating in Europe Biguanides Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!